Skip to content
Review Open access

Spinal cord stimulation in the setting of oncologic pain: a systematic review

2026 · Hospice & Palliative Medicine International Journal · 0 citations

Abstract

Background: Cancer-related pain remains a major clinical challenge, particularly when neuropathic or refractory to pharmacologic and interventional measures. Spinal cord stimulation (SCS) has been increasingly recognized as a potential therapy for select patients with cancer-related pain. Objective: This study aims to systematically review the evidence on the effectiveness, safety, and clinical applicability of SCS for cancer-related pain. Methods: A structured search of PubMed, MEDLINE, Embase, and Cochrane databases (inception to 2025) was performed for studies evaluating SCS for cancer-related pain. Eligible study types included randomized controlled trials (RCTs), observational studies, prospective/retrospective cohorts, case series, and case reports. Outcomes included pain relief, functional improvement, opioid reduction, durability, and complications. Results: Thirty-four studies met inclusion criteria (0 RCTs, 5 cohort studies, 29 case series/reports), comprising 204 patients. Most studies involved neuropathic pain due to tumor infiltration, post-surgical nerve injury, radiation-induced neuropathy, or chemotherapy-induced peripheral neuropathy. Across these studies it was found that 60-80% of patients achieved ≥50% pain relief during trial stimulation and 50-70% maintained benefit at follow-up (weeks to years). Opioid reduction was reported in 30-60% of cases. Complication rates were comparable to non-cancer SCS populations but theoretically increased by immunosuppression and coagulopathy. However, evidence quality was uniformly low due to publication bias, small samples, and heterogeneity. Conclusion: SCS appears to provide meaningful pain relief for select patients with refractory cancer-related neuropathic pain; however, the evidence is limited to small observational studies, with no RCTs. Multidisciplinary selection and individualized risk-benefit assessment remain crucial. High-quality comparative trials and prospective registries are needed.

Read PDF

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.